Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for cancer, including the marketed drug QINLOCK for gastrointestinal stromal tumors and a pipeline of investigational drugs.
Services
Deciphera Pharmaceuticals develops innovative science aimed at providing hope to people living with cancer. The company harnesses its proprietary drug discovery platform to design switch-control kinase inhibitors. It offers a diverse pipeline of drug candidates to improve patients' quality of life. Additionally, Deciphera conducts clinical studies and provides an Expanded Access Program (EAP) for investigational medicines under specific conditions.
Products
Deciphera Pharmaceuticals markets QINLOCK (ripretinib), a treatment specifically designed for gastrointestinal stromal tumors (GIST). The company's diverse pipeline includes several investigational drug candidates such as ripretinib, vimseltinib, and DCC-3116. These products aim to address unmet medical needs and advance cancer treatment.
Sector
Deciphera Pharmaceuticals operates within the biopharmaceutical sector, focusing primarily on cancer therapeutics. Utilizing a proprietary drug discovery platform, the company is dedicated to designing innovative treatments that target the underlying mechanisms of cancer, specifically through the development of switch-control kinase inhibitors.
Locations
Deciphera Pharmaceuticals is headquartered in Waltham, MA, and maintains research facilities in Lawrence, KS. The company also operates additional offices across Europe, including locations in Switzerland, Germany, France, Italy, and Spain. These international offices support Deciphera's global research, development, and commercial operations.